Detalhe da pesquisa
1.
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.
Br J Cancer
; 127(11): 2034-2042, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36175621
2.
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
Br J Cancer
; 123(1): 81-91, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32376889
3.
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
Oncologist
; 24(8): 1128-1136, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31015312
4.
LKB1 and Tumor Metabolism: The Interplay of Immune and Angiogenic Microenvironment in Lung Cancer.
Int J Mol Sci
; 20(8)2019 Apr 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30995715
5.
CheckMate 9LA: broadening treatment options for patients with non-small-cell lung cancer.
Lancet Oncol
; 22(2): 157-159, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33476592
6.
Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
Cancer
; 126(11): 2594-2596, 2020 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32154916
7.
Uncommon and Rare EGFR Mutations in Non-Small Cell Lung Cancer Patients with a Focus on Exon 20 Insertions and the Phase 3 PAPILLON Trial: The State of the Art.
Cancers (Basel)
; 16(7)2024 Mar 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38611009
8.
Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
Lung Cancer
; 187: 107441, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38141488
9.
Stage III Non-Small-Cell Lung Cancer: An Overview of Treatment Options.
Curr Oncol
; 30(3): 3160-3175, 2023 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36975452
10.
Adjuvant Treatments for Surgically Resected Non-Small Cell Lung Cancer Harboring EGFR Mutations: A Review.
JAMA Oncol
; 9(8): 1124-1131, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37166792
11.
Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
Curr Oncol
; 30(5): 5072-5092, 2023 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37232842
12.
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review.
Cancer Treat Rev
; 119: 102602, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37481836
13.
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations.
Cancers (Basel)
; 15(20)2023 Oct 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37894445
14.
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.
Cancers (Basel)
; 15(19)2023 Sep 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37835473
15.
Sharing Experience with Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitors in Lung Cancer: An Italian Expert Panel Discussion.
Curr Oncol
; 30(11): 10033-10042, 2023 Nov 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-37999149
16.
Association between Contrast-Enhanced Computed Tomography Radiomic Features, Genomic Alterations and Prognosis in Advanced Lung Adenocarcinoma Patients.
Cancers (Basel)
; 15(18)2023 Sep 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37760521
17.
Neoadjuvant Chemotherapy Plus Immunotherapy in Early-Stage Resectable Non-Small-Cell Lung Cancer.
J Clin Oncol
; 40(25): 2871-2877, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35714306
18.
Uncommon EGFR Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.
Curr Oncol
; 29(1): 255-266, 2022 01 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35049698
19.
Gene network Analysis Defines a Subgroup of Small Cell Lung Cancer patients With Short Survival.
Clin Lung Cancer
; 23(6): 510-521, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35739016
20.
Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50.
Front Oncol
; 12: 980765, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36033444